Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 11, 2015, Pages 2281-2289

  Talmud, Philippa J ^a   Holmes, Michael V ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

darapladib; Mendelian randomization; secretory phospholipase IIA; varespladib

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DARAPLADIB; SECRETORY PHOSPHOLIPASE A2; VARESPLADIB; ACETIC ACID DERIVATIVE; BENZALDEHYDE DERIVATIVE; BIOLOGICAL MARKER; INDOLE DERIVATIVE; OXIME; PHOSPHOLIPASE A2 INHIBITOR; PLA2G7 PROTEIN, HUMAN;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; BLOOD; CORONARY DISEASE; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETATES; ANIMALS; BENZALDEHYDES; BIOMARKERS; CORONARY DISEASE; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; OXIMES; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2, SECRETORY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84945492844     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305234     Document Type: Article

References (61)

1. Fordyce CB, Roe MT, Ahmad T, Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 2015 65 1567 1582. doi: 10.1016/j.jacc.2015.03.016
2. DiMasi JA, Grabowski HG, Hansen RW, The cost of drug development. N Engl J Med 2015 372 1972. doi: 10.1056/NEJMc1504317
3. Mullin R, Tufts study finds big rise 'in cost of drug development'. Chemical and Engineering News 2014 92 6
4. Lawlor DA, Windmeijer F, Smith GD, Is Mendelian randomization 'lost in translation?': comments on 'Mendelian randomization equals instrumental variable analysis with genetic instruments' by Wehby et al. Stat Med 2008 27 2750 2755. doi: 10.1002/sim.3308
5. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P, The support of human genetic evidence for approved drug indications. Nat Genet 2015 47 856 860. doi: 10.1038/ng.3314
6. Quehenberger O, Dennis EA, The human plasma lipidome. N Engl J Med 2011 365 1812 1823. doi: 10.1056/NEJMra1104901
7. Six DA, Dennis EA, The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000 1488 1 19
8. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G, Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011 111 6130 6185. doi: 10.1021/cr200085w
9. Murakami M, Kudo I, Phospholipase A2. J Biochem 2002 131 285 292
10. Murakami M, Sato H, Miki Y, Yamamoto K, Taketomi Y, A New Era of Secreted Phospholipase A2 (sPLA2). J Lipid Res 2015;56:1248-1261.
11. Small DM, George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988 8 103 129
12. Hurt-Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg E, Johansen B, Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 1997 17 300 309
13. Jönsson-Rylander AC, Lundin S, Rosengren B, Pettersson C, Hurt-Camejo E, Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 2008 10 252 259
14. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W, Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995 118 173 181
15. Rosengren B, Peilot H, Umaerus M, Jonsson-Rylander AC, Mattsson-Hulten L, Hallberg C, Cronet P, Rodriguez-Lee M, Hurt-Camejo E, Secretory Phospholipase A2 Group V Lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol 2006 26 1579 1585
16. McNamara JR, Small DM, Li Z, Schaefer EJ, Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res 1996 37 1924 1935
17. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E, Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999 274 25913 25920
18. Gesquiere L, Cho W, Subbaiah PV, Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 2002 41 4911 4920
19. Henderson WR Jr, Chi EY, Bollinger JG, Tien YT, Ye X, Castelli L, Rubtsov YP, Singer AG, Chiang GK, Nevalainen T, Rudensky AY, Gelb MH, Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med 2007 204 865 877. doi: 10.1084/jem.20070029
20. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ, Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999 19 1284 1290
21. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR, Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007 27 600 606. doi: 10.1161/01.ATV.0000257133.60884.44
22. Curfs DM, Ghesquiere SA, Vergouwe MN, van der Made I, Gijbels MJ, Greaves DR, Verbeek JS, Hofker MH, de Winther MP, Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem 2008 283 21640 21648. doi: 10.1074/jbc.M710584200
23. Ait-Oufella H, Herbin O, Lahoute C, Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2013 33 466 473. doi: 10.1161/ATVBAHA.112.300309
24. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR, Can animal models of disease reliably inform human studies? PLoS Med 2010 7 e1000245. doi: 10.1371/journal.pmed.1000245
25. 2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010 122 2183 2200. doi: 10.1161/CIRCULATIONAHA.110.936393
26. Radvanyi F, Jordan L, Russo-Marie F, Bon C, A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. Anal Biochem 1989 177 103 109. doi: 10.1016/0003-2697(89)90022-5
27. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM, Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007 27 1177 1183. doi: 10.1161/ATVBAHA.107.139352
28. Mallat Z, Steg PG, Benessiano J, Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005 46 1249 1257. doi: 10.1016/j.jacc.2005.06.056
29. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT, Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005 25 839 846. doi: 10.1161/01.ATV.0000157933.19424.b7
30. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH, Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003 24 1824 1832. doi: 10.1016/j.ehj.2003.07.003
31. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D, Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009 30 2742 2748. doi: 10.1093/eurheartj/ehp302
32. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H, Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000 86 718 722. doi: 10.1016/S0002-9149(00)01069-9
33. Hartford M, Wiklund O, Mattsson Hultén L, Perers E, Person A, Herlitz J, Hurt-Camejo E, Karlsson T, Caidahl K, CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006 108 55 62. doi: 10.1016/j.ijcard.2005.04.004
34. Porela P, Pulkki K, Voipio-Pulkki LM, Pettersson K, Leppänen V, Nevalainen TJ, Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res Cardiol 2000 95 413 417
35. O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SD, Braunwald E, Tedgui A, Sabatine MS, Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem 2011 57 1311 1317. doi: 10.1373/clinchem.2011.166520
36. Holmes MV, Simon T, Exeter HJ, Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013 62 1966 1976. doi: 10.1016/j.jacc.2013.06.044
37. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM, Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999 274 7018 7024. doi: 10.1074/jbc.274.11.7018
38. Tsimikas S, Tsironis LD, Tselepis AD, New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007 27 2094 2099. doi: 10.1161/01.ATV.0000280571.28102.d4
39. Tselepis AD, Karabina SA, Stengel D, Piédagnel R, Chapman MJ, Ninio E, N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 2001 42 1645 1654
40. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM, Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996 97 2784 2791. doi: 10.1172/JCI118733
41. Häkkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ, Tew DG, Karkola K, Ylä-Herttuala S, Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999 19 2909 2917
42. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, Leake DS, Arends MJ, Mitchinson MJ, Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001 505 357 363. doi: 10.1016/S0014-5793(01)02840-X
43. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P, Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001 103 2495 2500. doi: 10.1161/01.CIR.103.20.2495
44. Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K, Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003 23 829 835. doi: 10.1161/01.ATV.0000067701.09398.18
45. Thompson A, Gao P, Orfei L, Watson S, Di AE, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 375 1536 1544
46. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD, Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000 343 1148 1155. doi: 10.1056/NEJM200010193431603
47. Rosenson RS, Fraser H, Trias J, Hislop C, Varespladib methyl in cardiovascular disease. Expert Opin Investig Drugs 2010 19 1245 1255. doi: 10.1517/13543784.2010.517193
48. Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J, Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/-mice. J Cardiovasc Pharmacol 2009 53 60 65. doi: 10.1097/FJC.0b013e318195bfbc
49. Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD, PLASMA Investigators Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009 373 649 658. doi: 10.1016/S0140-6736(09)60403-7
50. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D, Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010 56 1079 1088. doi: 10.1016/j.jacc.2010.06.015
51. Riley RF, Corson MA, Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs 2009 12 648 655
52. Zalewski A, Macphee C, Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005 25 923 931. doi: 10.1161/01.ATV.0000160551.21962.a7
53. Exeter HJ, Folkersen L, Palmen J, Franco-Cereceda A, Cooper JA, Kalea AZ, Hooft FV, Eriksson P, Humphries SE, Talmud PJ, Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels. PLoS One 2012 7 e41139. doi: 10.1371/journal.pone.0041139
54. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, VISTA-16 Investigators Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014 311 252 262. doi: 10.1001/jama.2013.282836
55. Casas JP, Ninio E, Panayiotou A, PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010 121 2284 2293. doi: 10.1161/CIRCULATIONAHA.109.923383
56. Polfus LM, Gibbs RA, Boerwinkle E, Coronary heart disease and genetic variants with low phospholipase A2 activity. N Engl J Med 2015 372 295 296. doi: 10.1056/NEJMc1409673
57. O'Donoghue ML, Braunwald E, White HD, SOLID-TIMI 52 Investigators Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014 312 1006 1015. doi: 10.1001/jama.2014.11061
58. White HD, Held C, Stewart R, Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014 370 1702 1711. doi: 10.1056/NEJMoa1315878
59. Holmes MV, Exeter HJ, Folkersen L, CARDIoGRAM Consortium Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet 2014 7 144 150. doi: 10.1161/CIRCGENETICS.113.000271
60. Guardiola M, Exeter HJ, Perret C, PLA2G10 gene variants, sPLA2 activity, and coronary heart disease risk. Circ Cardiovasc Genet 2015 8 356 362. doi: 10.1161/CIRCGENETICS.114.000633
61. 2 is protective from coronary artery disease in South Korean males. PLoS One 2011 6 e18208. doi: 10.1371/journal.pone.0018208